Centric Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$222K Buy
+403
New +$206K 0.03% 208
2022
Q4
– Sell
-885
Closed -$256K – 122
2022
Q3
$256K Buy
+885
New +$255K 0.1% 105

Other funds holding VRTX

Centric Wealth Management's VRTX Position: Q3 2026 in Review

Centric Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 403 shares worth $222K. The stake represents 0.03% of the portfolio and ranks #208 among its holdings. This is a return to the name: Centric Wealth Management previously reported a position in VRTX as recently as Q3 2022.

Centric Wealth Management first reported a position in VRTX in Q3 2022 and has held it in 2 quarters since. The position peaked at $256K in Q3 2022. 1,775 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Centric Wealth Management held 403 shares of Vertex Pharmaceuticals worth $222K as of Q3 2026.
  • Vertex Pharmaceuticals was a new Centric Wealth Management position in Q3 2026.
  • Vertex Pharmaceuticals made up 0.03% of Centric Wealth Management's portfolio in Q3 2026, its #208 holding.
  • Centric Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
  • Centric Wealth Management's Vertex Pharmaceuticals position peaked at $256K in Q3 2022.
  • 1,775 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Centric Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.